Coronado Biosciences (CNDO -1.9%) slips this morning, despite announcing earlier that it's completed the enrollment of 250 patients for its Phase 2 clinical trial of TSO, a natural immunomodulator that regulates T-Cells and pro-inflammatory cytokines to treat Crohn's disease. The trial is a U.S. multicenter study designed to evaluate the safety and efficacy of the treatment, with results from a second interim analysis expected in H213.
Coronado Biosciences (CNDO -1.9%) slips this morning, despite announcing earlier that it's...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs